Melanoma: [68Ga]Ga-FAPI PET/CT Imaging Study

We are testing a new imaging method to see how well immune checkpoint inhibitor therapy works in patients with advanced melanoma. This study aims to improve response evaluation during treatment.

6-12 months≤5 visitsEfficacy phase (II)No PlaceboInvestigational MedicinesInjectionDermatologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Fludeoxyglucose (18f)
Fludeoxyglucose (18F) is a radioactive tracer used in PET scans to highlight areas of high metabolic activity, often for detecting cancer.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

68Ga-FAPI-46

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Rigshospitalet
Management
Copenhagen, Denmark
Herlev Hospital
Department of Oncology
Rødovre, Denmark
Sponsor: Rigshospitalet
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.